$1.03 Earnings Per Share Expected for China Biologic Products Holdings Inc (NASDAQ:CBPO) This Quarter

Analysts expect that China Biologic Products Holdings Inc (NASDAQ:CBPO) will report earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings of $1.17 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 12%. The company is expected to issue its next earnings report on Friday, August 2nd.

On average, analysts expect that China Biologic Products will report full-year earnings of $4.01 per share for the current year, with EPS estimates ranging from $3.93 to $4.09. For the next fiscal year, analysts anticipate that the business will post earnings of $4.24 per share, with EPS estimates ranging from $3.95 to $4.52. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover China Biologic Products.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $129.78 million during the quarter, compared to the consensus estimate of $119.50 million. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. During the same quarter last year, the firm earned $1.21 earnings per share.

A number of equities analysts recently weighed in on the stock. BidaskClub raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a research note on Wednesday, June 19th. Jefferies Financial Group downgraded shares of China Biologic Products from a “hold” rating to an “underperform” rating and lowered their target price for the stock from $67.00 to $62.00 in a research note on Monday, March 11th. ValuEngine raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Credit Suisse Group set a $88.00 target price on shares of China Biologic Products and gave the stock a “hold” rating in a research note on Friday, March 8th. Finally, Zacks Investment Research raised shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a research note on Monday, May 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. China Biologic Products presently has a consensus rating of “Hold” and a consensus target price of $78.00.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Maso Capital Partners Ltd raised its stake in China Biologic Products by 3.3% during the 1st quarter. Maso Capital Partners Ltd now owns 164,500 shares of the biopharmaceutical company’s stock worth $15,011,000 after acquiring an additional 5,300 shares during the period. Greenwoods Asset Management Ltd raised its stake in China Biologic Products by 281.8% during the 1st quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock worth $43,762,000 after acquiring an additional 353,980 shares during the period. FIL Ltd raised its stake in China Biologic Products by 1.8% during the 1st quarter. FIL Ltd now owns 519,071 shares of the biopharmaceutical company’s stock worth $47,365,000 after acquiring an additional 8,929 shares during the period. Dalton Investments LLC raised its stake in China Biologic Products by 51.1% during the 1st quarter. Dalton Investments LLC now owns 113,851 shares of the biopharmaceutical company’s stock worth $10,389,000 after acquiring an additional 38,500 shares during the period. Finally, Alpine Global Management LLC bought a new stake in China Biologic Products during the 1st quarter worth approximately $480,000. 35.28% of the stock is owned by institutional investors and hedge funds.

CBPO stock opened at $95.30 on Friday. The company’s fifty day simple moving average is $92.06. The company has a market capitalization of $3.74 billion, a P/E ratio of 23.71, a P/E/G ratio of 4.91 and a beta of 1.27. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $107.44.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.